EGFR and lung adenocarcinoma: In our study, the enrolled patients without brain metastases had a relatively good ECOG PS compared with those with brain metastases, but PS status in afatinib as first-line treatment in patients with EGFR mutation-positive lung adenocarcinoma did not yield a difference in OS after multivariate analyses.